#India #Everest Group #pharmaceuticals #Hyderabad #Excelra

Excelra: Leading the Way in Pharmaceutical R&D IT Services

Excelra, a global leader in data and informatics for life sciences, has recently been recognized by the Everest Group as a leader in the PEAK Matrix® Assessment for Pharmaceutical R&D IT Services 2026. This evaluation considered 34 different service providers and underscored Excelra's impactful presence in the market due to its commitment to data quality, scientific rigor, and advanced AI capabilities.

One of the key contributors to Excelra’s top ranking is its flagship product, GOSTAR®, which stands out with a comprehensive dataset containing 37 million bioactivity data points. This product is designed to be ready for AI and machine learning, enhancing decision-making in drug discovery processes. Excelra’s AI-driven scientific solutions leverage high-quality scientific data to cater specifically to R&D needs in life sciences, achieving a unique synergy that combines rapid analysis and actionable insights.

The Everest Group attributes Excelra’s success to its meticulous mix of data, scientific principles, and industry expertise, emphasizing the importance of solid partnerships in the sector. According to Durga Ambati, Vice President at Everest Group, “Pharmaceutical companies prefer partners with deep scientific and functional expertise alongside robust data, AI, and platform capabilities.” Excelra's proprietary scientific datasets, especially GOSTAR, enhance its reputation by supporting AI-driven Structure-Activity Relationship (SAR) intelligence that is crucial in pharmaceutical exploration.

Furthermore, the company has bolstered its capabilities through recent strategic acquisitions, enhancing its on-site scientific consulting prowess and aligning closely with international clients. With a robust ecosystem of partners that includes prominent cloud service providers, laboratory informatics, and technology platforms, Excelra is well-equipped to meet evolving industry demands.

Anandbir Brar, CEO of Excelra, remarked, “Science comes first. This is a conviction we have never compromised on, and this recognition validates that belief.” In today’s landscape of pharmaceutical R&D, the balance of scientific rigor and project scale is paramount, especially as AI technology becomes increasingly integrated within R&D initiatives. Brar expressed gratitude toward Excelra's clients for their trust in the company’s capabilities for critical projects, as well as his pride in the dedicated teams whose expertise made this recognition possible.

For organizations in the pharmaceutical sector, the integration of advanced AI with science-driven methodologies is no longer a luxury; it is a necessity. Excelra continues to lead the charge, underpinned by a vision to transform complexity in R&D into defensible decisions that drive meaningful advancements in drug discovery.

To learn more about Excelra’s recognition in the Everest Group’s assessment, visit Excelra's official website. Their commitment to data-driven decision-making and scientific rigor sets the standard for the industry as a whole.

About Excelra

Excelra’s engineers are dedicated to AI-driven R&D, integrating data and AI-ready platforms with connected laboratory informatics and multi-omics expertise to simplify the challenges of R&D into defensible outcomes. For more information, visit Excelra.com.

About Everest Group

Everest Group is a leading research firm that guides business leaders to make informed decisions. They assist clients in navigating today’s market challenges while enhancing strategies through tailored problem-solving approaches. More information can be found at EverestGroup.com.